Published in Infection on March 31, 2008
Clinical characteristics of patients with Epstein Barr virus in cerebrospinal fluid. BMC Infect Dis (2011) 0.94
HSV-1 and Alzheimer's disease: more than a hypothesis. Front Pharmacol (2014) 0.91
Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity. Eur J Clin Microbiol Infect Dis (2011) 0.87
CSF herpes virus and autoantibody profiles in the evaluation of encephalitis. Neurol Neuroimmunol Neuroinflamm (2016) 0.81
Autophagy interaction with herpes simplex virus type-1 infection. Autophagy (2016) 0.77
Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods (2000) 1.71
Serological pattern "anti-HBc alone": report on a workshop. J Med Virol (2000) 1.65
Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol (1995) 1.57
Hepatitis C - contamination of toothbrushes: myth or reality? J Viral Hepat (2006) 1.48
Hepatitis B vaccination: how long does protection last? Lancet (1984) 1.43
Clinical evaluation of a recombinant hepatitis B vaccine. Lancet (1984) 1.33
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol (2011) 1.24
Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol (2008) 1.20
Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant (2004) 1.17
Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat (2007) 1.10
The economic burden of hepatitis B in Germany. Eur J Epidemiol (2000) 1.05
Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance. Vaccine (1997) 1.05
Expression of the Epstein-Barr virus 138-kDa early protein in Escherichia coli for the use as antigen in diagnostic tests. Gene (1986) 1.05
Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines. J Virol (1994) 1.05
Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia. Proc Natl Acad Sci U S A (1991) 1.03
Detection of hepatitis B virus in serum using amplification of viral DNA by means of the polymerase chain reaction. J Med Virol (1989) 1.03
Quantitative PCR. A survey of the present technology. Mol Biotechnol (1995) 1.03
Results of immunisation with a recombinant yeast-derived hepatitis B vaccine. J Infect (1986) 1.02
In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob Agents Chemother (2000) 1.01
Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Euro Surveill (2010) 0.99
Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet (1990) 0.99
Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J Virol (1998) 0.98
p53 wild-type and p53 nullizygous Big Blue transgenic mice have similar frequencies and patterns of observed mutation in liver, spleen and brain. Oncogene (1995) 0.98
Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors. Dig Dis (2001) 0.94
Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol (1999) 0.93
Neurological and psychiatric practitioners' views on Alzheimer's disease and treatment thereof. Dement Geriatr Cogn Disord (2008) 0.92
Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med (1996) 0.91
Diphtheria booster vaccination: one or two injections? Vaccine (1999) 0.91
Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol (2009) 0.90
Foodborne hepatitis A outbreak associated with bakery products in northern Germany, 2012. Euro Surveill (2014) 0.90
Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine (1997) 0.90
Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection (2006) 0.90
A novel deletion mutant of hepatitis B virus surface antigen. J Med Virol (1999) 0.90
Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol (2007) 0.89
Detection of hepatitis B virus DNA in serum by a rapid filtration-hybridization assay. J Virol Methods (1985) 0.88
Antibody responses and skin reactivity after intradermal hepatitis B virus vaccine. Lancet (1984) 0.88
Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. Neurobiol Aging (2007) 0.87
Substantial decline of notified hepatitis B in major parts of Europe after 1985. Scand J Infect Dis (1994) 0.85
Immune responses to late booster doses of hepatitis B vaccine. J Med Virol (1985) 0.85
Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers. Virology (1999) 0.85
Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. J Med Virol (1999) 0.85
Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination. Infection (2007) 0.85
First sequence-confirmed case of infection with the new influenza A(H1N1) strain in Germany. Euro Surveill (2009) 0.83
Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang (2010) 0.83
Passive/active immunization against hepatitis B. J Infect Dis (1984) 0.83
Low hepatitis B immunogenicity of a hexavalent vaccine widely used in Germany: results of the German Health Survey for Children and Adolescents, 2003-2006. Epidemiol Infect (2010) 0.83
Spontaneous mutation frequencies and spectra in p53 (+/+) and p53 (-/-) mice: a test of the 'guardian of the genome' hypothesis in the Big Blue transgenic mouse mutation detection system. Mutat Res (1997) 0.83
Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine (2000) 0.83
Germline mosaicism in a female who seemed to be a carrier by sequence analysis. Hum Mol Genet (1995) 0.83
Evaluation of a reduced dose of hepatitis B vaccine administered intradermally. J Med Virol (1984) 0.82
Immune responses to active and passive-active vaccination against hepatitis B. J Infect (1983) 0.82
Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Toxicol Lett (1995) 0.82
Fibrinogen of relatively high solubility, III. Residual clottable material in plasma deprived of the majority of fibrinogen. Hoppe Seylers Z Physiol Chem (1974) 0.82
Isolation of residual fibrinogen from a supernatant of plasma precipitated with 2.1 M glycine. Thromb Res (1976) 0.82
Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transpl Infect Dis (2011) 0.81
Hepatitis C virus transmission in a pediatric oncology ward: analysis of an outbreak and review of the literature. Lab Invest (2001) 0.81
Delayed facial palsy following uneventful middle ear surgery: a herpes simplex virus type 1 reactivation? Ann Otol Rhinol Laryngol (1998) 0.81
Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. Z Gastroenterol (2003) 0.81
Quantitative parameters for light microscopic assessment of the tubuli seminiferi. Fertil Steril (1976) 0.81
[Laryngeal chondrosarcoma]. Otolaryngol Pol (1997) 0.80
Efficient foreign gene expression in Epstein-Barr virus-transformed human B-cells. Virology (1994) 0.79
Hemochromatosis mutation in hepatitis C: histopathology. Gastroenterology (1998) 0.79
The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat (2008) 0.79
Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? Vaccine (2000) 0.79
Outcome of an exercise to notify patients treated by a general surgeon infected with the hepatitis C virus. J Clin Virol (2008) 0.79
[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. Z Gastroenterol (2007) 0.79
Strategies for the economic preparation of Epstein-Barr virus proteins of diagnostic and protective value by genetic engineering: a new approach based on segments of virus-encoded gene products. IARC Sci Publ (1984) 0.79
Does the pattern of atrophy of the Corpus callosum differ between patients with frontotemporal dementia and patients with Alzheimer's disease? Dement Geriatr Cogn Disord (2004) 0.78
No evidence of XMRV infection in immunocompromised patients and HIV-positive individuals from Germany. Infection (2012) 0.78
[Polymerase chain reaction (PCR) for microbiological diagnosis in refractory infectious keratitis: a clinical study in 16 patients]. Klin Monbl Augenheilkd (2000) 0.77
Persistence of anti-HBs after intradermal inoculation of reduced doses of hepatitis B vaccine. Lancet (1984) 0.77
Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc Eur Dial Transplant Assoc (1983) 0.77
Vaccination against hepatitis B in patients with renal insufficiency. Proc Eur Dial Transplant Assoc Eur Ren Assoc (1985) 0.77
Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? Pharmacopsychiatry (2010) 0.76
Hepatitis B surface antigen (HBsAg) subtype-specific antibodies in persons vaccinated against hepatitis B. J Med Virol (1984) 0.76
Lymphocyte surface proteins recognized by an anti-thymocyte-globulin. Hoppe Seylers Z Physiol Chem (1981) 0.76
Identification of novel mutations in the NPC1 gene in German patients with Niemann-Pick C disease. J Inherit Metab Dis (2002) 0.75
[Combined vaccine against tetanus, diphtheria and polio. A randomized controlled study of immunogenicity and tolerance]. Fortschr Med Orig (2001) 0.75
[Immunoprophylaxis of hepatitis B. 2. Active immunization: vaccine production, vaccine safety, side effects]. Dtsch Med Wochenschr (1983) 0.75
Radio-iodinated surface proteins of electrophoretically separated rat lymphocytes. Hoppe Seylers Z Physiol Chem (1980) 0.75
[Vaccination of uremic patients against hepatitis B]. Dtsch Med Wochenschr (1983) 0.75
[Immunoprophylaxis of hepatitis B. 3. Results of clinical studies with hepatitis B vaccines]. Dtsch Med Wochenschr (1983) 0.75
Quantitative PCR : a survey of the present technology. Methods Mol Med (1999) 0.75
[Diagnosis, progression and therapy of hepatitis-B-virus infection--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network]. Z Gastroenterol (2004) 0.75
[Success of hepatitis B vaccination]. Dtsch Med Wochenschr (1984) 0.75
[Immunoprophylaxis of hepatitis B. 4. Identification of risk groups, recommendations for inoculation, new developments]. Dtsch Med Wochenschr (1983) 0.75
[Autochthonous hepatitis E-virus infection as cause of acute hepatitis in Germany - a case report]. Z Gastroenterol (2011) 0.75
[Immunoprophylaxis in hepatitis B. 1. Passive immunization]. Dtsch Med Wochenschr (1983) 0.75
[New TBE vaccine formulations--free of proteineous stabilizer and preservatives. Overview of clinical studies and first year post-marketing experience]. MMW Fortschr Med (2004) 0.75
[Hepatitis B and the delta agent]. Fortschr Med (1984) 0.75
[Bifocal cancer of the maxillary sinus]. Otolaryngol Pol (1972) 0.75